Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Fuji
McKesson
Harvard Business School
Cantor Fitzgerald
Citi
Farmers Insurance
Healthtrust
Moodys
Colorcon

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,939,971

« Back to Dashboard

Which drugs does patent 6,939,971 protect, and when does it expire?

Patent 6,939,971 protects DEXILANT and DEXILANT SOLUTAB and is included in two NDAs.

Protection for DEXILANT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-four patent family members in twenty-five countries.
Summary for Patent: 6,939,971
Title: Benzimidazole compound crystal
Abstract:A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1 H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
Inventor(s): Fujishima; Akira (Sanda, JP), Aoki; Isao (Kawanishi, JP), Kamiyama; Keiji (Ibaraki, JP)
Assignee: Takeda Pharmaceutical Company, Ltd. (Osaka, JP)
Application Number:10/655,114
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,939,971

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-001 Jan 30, 2009 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-002 Jan 30, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa DEXILANT SOLUTAB dexlansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 208056-001 Jan 26, 2016 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,939,971

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan11-171509Jun 17, 1999

Non-Orange Book US Patents Family Members for Patent 6,939,971

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,462,058 Benzimidazole compound crystal ➤ Subscribe
8,552,198 Benzimidazole compound crystal ➤ Subscribe
7,737,282 Benzimidazole compound crystal ➤ Subscribe
9,145,389 Benzimidazole compound crystal ➤ Subscribe
8,030,333 Benzimidazole compound crystal ➤ Subscribe
6,664,276 Benzimidazole compound crystal ➤ Subscribe
7,339,064 Benzimidazole compound crystal ➤ Subscribe
7,569,697 Benzimidazole compound crystal ➤ Subscribe
8,884,019 Benzimidazole compound crystal ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,939,971

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I289557 ➤ Subscribe
Taiwan I275587 ➤ Subscribe
Slovenia 1129088 ➤ Subscribe
Portugal 1977751 ➤ Subscribe
Portugal 1129088 ➤ Subscribe
Poland 201068 ➤ Subscribe
Poland 352193 ➤ Subscribe
New Zealand 515702 ➤ Subscribe
Norway 321168 ➤ Subscribe
Norway 20016087 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Mallinckrodt
Colorcon
Deloitte
Fish and Richardson
Express Scripts
Citi
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot